{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T22:59:05Z","timestamp":1793228345708,"version":"4.5.0"},"reference-count":60,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Investigation"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.resinv.2026.101434","type":"journal-article","created":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:54:45Z","timestamp":1777596885000},"page":"101434","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Emerging therapies and translational advances in small cell lung cancer: Overcoming resistance"],"prefix":"10.1016","volume":"64","author":[{"given":"Yuya","family":"Nishii","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-6395-2807","authenticated-orcid":false,"given":"Yoh","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4896-5824","authenticated-orcid":false,"given":"Tatsuya","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.resinv.2026.101434_bib1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41572-020-00235-0","article-title":"Small-cell lung cancer","volume":"7","author":"Rudin","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.resinv.2026.101434_bib2","doi-asserted-by":"crossref","first-page":"8","DOI":"10.5334\/aogh.2419","article-title":"Global epidemiology of lung cancer","volume":"85","author":"Barta","year":"2019","journal-title":"Ann Glob Health"},{"key":"10.1016\/j.resinv.2026.101434_bib3","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","article-title":"First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer","volume":"379","author":"Horn","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.resinv.2026.101434_bib4","first-page":"107567","article-title":"Five-year survival in patients with extensive-stage small cell lung cancer treated with atezolizumab in IMpower133 and IMbrella A","volume":"192","author":"Liu","year":"2024","journal-title":"Lung Cancer"},{"key":"10.1016\/j.resinv.2026.101434_bib5","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1016\/S0140-6736(19)32222-6","article-title":"Durvalumab plus platinum\u2013etoposide versus platinum\u2013etoposide for ES-SCLC (CASPIAN)","volume":"394","author":"Paz-Ares","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.resinv.2026.101434_bib6","first-page":"629","article-title":"Consolidation durvalumab after chemoradiotherapy in LS-SCLC (ADRIATIC)","volume":"388","author":"O'Brien","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.resinv.2026.101434_bib7","first-page":"1671","article-title":"Tarlatamab in recurrent SCLC","volume":"389","author":"Rudin","year":"2023","journal-title":"N Engl J Med"},{"issue":"suppl 16","key":"10.1016\/j.resinv.2026.101434_bib8","first-page":"8505","article-title":"Obrixtamig in relapsed\/refractory SCLC: phase I","volume":"41","author":"Johnson","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.resinv.2026.101434_bib9","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aac9459","article-title":"DLL3-targeted ADC eradicates neuroendocrine tumor-initiating cells","volume":"7","author":"Saunders","year":"2015","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.resinv.2026.101434_bib10","article-title":"ADCs in SCLC: a new era?","volume":"8","author":"Khalifa","year":"2023","journal-title":"ESMO Open"},{"key":"10.1016\/j.resinv.2026.101434_bib11","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1056\/NEJMoa003034","article-title":"CPT-11 + CDDP vs VP-16 + CDDP for ES-SCLC","volume":"346","author":"Noda","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.resinv.2026.101434_bib12","doi-asserted-by":"crossref","first-page":"5441","DOI":"10.1200\/JCO.2006.06.5821","article-title":"Oral topotecan vs supportive care in relapsed SCLC","volume":"24","author":"O'Brien","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.resinv.2026.101434_bib13","doi-asserted-by":"crossref","first-page":"5401","DOI":"10.1200\/JCO.2008.18.1974","article-title":"Amrubicin vs topotecan (JCOG0509)","volume":"26","author":"Inoue","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.resinv.2026.101434_bib14","doi-asserted-by":"crossref","first-page":"3823","DOI":"10.1200\/JCO.2017.72.5069","article-title":"Pembrolizumab KEYNOTE-028","volume":"35","author":"Ott","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.resinv.2026.101434_bib15","first-page":"e23","article-title":"KEYNOTE-028\/158 pooled analysis","volume":"15","author":"Chung","year":"2020","journal-title":"J Thorac Oncol"},{"issue":"suppl 15","key":"10.1016\/j.resinv.2026.101434_bib16","first-page":"9001","article-title":"KEYNOTE-604: Pembrolizumab + EP for ES-SCLC","volume":"39","author":"Paz-Ares","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.resinv.2026.101434_bib17","first-page":"883","article-title":"CheckMate 032 nivolumab \u00b1 ipilimumab","volume":"17","author":"Ready","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.resinv.2026.101434_bib18","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.jtho.2018.10.003","article-title":"CheckMate 032 updated results","volume":"14","author":"Ready","year":"2019","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.resinv.2026.101434_bib19","first-page":"1199","article-title":"CheckMate 331: nivolumab vs chemo","volume":"32","author":"O'Brien","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.resinv.2026.101434_bib20","article-title":"Lurbinectedin plus atezolizumab as maintenance therapy in extensive-stage small-cell lung cancer (IMforte): a phase III randomized trial","author":"Johnson","year":"2024","journal-title":"Lancet Oncol"},{"issue":"suppl 16","key":"10.1016\/j.resinv.2026.101434_bib21","article-title":"Lurbinectedin plus atezolizumab as maintenance therapy after first-line chemoimmunotherapy for ES-SCLC (IMforte)","volume":"42","author":"Johnson","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.resinv.2026.101434_bib22","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/s41568-019-0133-9","article-title":"SCLC molecular subtypes","volume":"19","author":"Rudin","year":"2019","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.resinv.2026.101434_bib23","first-page":"5380","article-title":"Lung NEN molecular profiling","volume":"12","author":"Bailey","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.resinv.2026.101434_bib24","first-page":"290","article-title":"Targeting SCLC based on subtypes","volume":"19","author":"Witkiewicz","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.resinv.2026.101434_bib25","article-title":"Microenvironment shapes SCLC neuroendocrine states","volume":"5","author":"Desai","year":"2024","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.resinv.2026.101434_bib26","first-page":"1234","article-title":"TME of SCLC not defined by molecular subtype","volume":"15","author":"Velut","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.resinv.2026.101434_bib27","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1158\/2159-8290.CD-17-0593","article-title":"HLA-I loss and ICI resistance","volume":"7","author":"Gettinger","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1016\/j.resinv.2026.101434_bib28","first-page":"303","article-title":"Bispecific T-cell engagers","volume":"7","author":"Baeuerle","year":"2023","journal-title":"Ann Rev Cancer Biol"},{"key":"10.1016\/j.resinv.2026.101434_bib29","first-page":"302ra136","article-title":"DLL3 ADC preclinical","volume":"7","author":"Saunders","year":"2015","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.resinv.2026.101434_bib30","first-page":"1981","article-title":"AMG 757 (tarlatamab) preclinical evidence","volume":"29","author":"He","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.resinv.2026.101434_bib31","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1056\/NEJMoa2307980","article-title":"Tarlatamab in previously treated SCLC","volume":"389","author":"Ahn","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.resinv.2026.101434_bib32","series-title":"FDA grants accelerated approval to tarlatamab","year":"2024"},{"key":"10.1016\/j.resinv.2026.101434_bib33","series-title":"DeLLphi 301 follow-up and 303 details","year":"2024"},{"key":"10.1016\/j.resinv.2026.101434_bib34","article-title":"Bispecific T-cell engagers in SCLC","volume":"14","author":"Zhu","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.resinv.2026.101434_bib35","first-page":"512","article-title":"DLL3 BiTE landscape review","volume":"17","author":"Aijaz","year":"2025","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.resinv.2026.101434_bib36","first-page":"2345","article-title":"Tarlatamab in small-cell lung cancer after platinum-based chemotherapy","volume":"392","author":"Mountzios","year":"2025","journal-title":"N Engl J Med"},{"issue":"suppl 16","key":"10.1016\/j.resinv.2026.101434_bib37","article-title":"Tarlatamab plus atezolizumab or durvalumab as maintenance therapy in ES-SCLC (DeLLphi-303)","volume":"42","author":"Ahn","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.resinv.2026.101434_bib38","unstructured":"."},{"issue":"suppl 16","key":"10.1016\/j.resinv.2026.101434_bib39","first-page":"8090","article-title":"MK-6070 phase I\/II","volume":"42","author":"Molloy","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.resinv.2026.101434_bib40","article-title":"QLS31904 preclinical","volume":"82","author":"Yang","year":"2022","journal-title":"Cancer Res"},{"key":"10.1016\/j.resinv.2026.101434_bib41","first-page":"719","article-title":"CD3\/CD137 trispecific DLL3 Ab","volume":"12","author":"Ji","year":"2024","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.resinv.2026.101434_bib42","first-page":"60","article-title":"DLL3-targeted therapies review","volume":"16","author":"Zheng","year":"2023","journal-title":"J Hematol Oncol"},{"issue":"suppl 16","key":"10.1016\/j.resinv.2026.101434_bib43","first-page":"TPS8128","article-title":"Peluntamig phase 1\/2 (SKYBRIDGE)","volume":"43","author":"Sands","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.resinv.2026.101434_bib44","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S1470-2045(16)30565-4","article-title":"Rovalpituzumab tesirine phase 1","volume":"18","author":"Rudin","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.resinv.2026.101434_bib45","first-page":"1398","article-title":"Rova-T vs topotecan phase II","volume":"37","author":"Pietanza","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.resinv.2026.101434_bib46","article-title":"A first-in-human phase 1 study of SHR-4849 (IDE849), a DLL3-directed antibody-drug conjugate, in relapsed small cell lung cancer","author":"Wang","year":"2025","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.resinv.2026.101434_bib47","first-page":"743","article-title":"DS-7300 FIH","volume":"29","author":"Ott","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.resinv.2026.101434_bib48","article-title":"HS20093 preclinical\/phase I","volume":"83","author":"Baek","year":"2023","journal-title":"Cancer Res"},{"key":"10.1016\/j.resinv.2026.101434_bib49","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1038\/s41591-025-03600-2","article-title":"YL201 phase 1\/1b","volume":"31","author":"Ma","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.resinv.2026.101434_bib50","article-title":"SEZ6-targeted ADC","volume":"20","author":"Giffin","year":"2021","journal-title":"Mol Cancer Therapeut"},{"issue":"suppl 16","key":"10.1016\/j.resinv.2026.101434_bib51","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1200\/JCO.2025.43.16_suppl.105","article-title":"ABBV-706 phase I","volume":"43","author":"Cooper","year":"2025","journal-title":"J Clin Oncol"},{"issue":"suppl 16","key":"10.1016\/j.resinv.2026.101434_bib52","first-page":"8571","article-title":"Sacituzumab govitecan (TROPiCS-03)","volume":"41","author":"Ready","year":"2023","journal-title":"J Clin Oncol"},{"issue":"suppl 2","key":"10.1016\/j.resinv.2026.101434_bib53","first-page":"LBA85","article-title":"SHR-A1921 phase I","volume":"35","author":"Liu","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.resinv.2026.101434_bib54","first-page":"3549","article-title":"DLL3 CAR-T in SCLC","volume":"27","author":"Wang","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.resinv.2026.101434_bib55","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1146\/annurev-med-062315-120245","article-title":"CAR-T for solid tumors review","volume":"68","author":"Newick","year":"2017","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.resinv.2026.101434_bib56","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T therapy strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.resinv.2026.101434_bib57","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"177Lu-DOTATATE","volume":"376","author":"Strosberg","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.resinv.2026.101434_bib58","first-page":"1558","article-title":"DLL3 radiolabeled antibodies","volume":"62","author":"Carter","year":"2021","journal-title":"J Nucl Med"},{"key":"10.1016\/j.resinv.2026.101434_bib38a","unstructured":"ClinicalTrials.gov. A study of BI 764532 (Obrixtamig) in patients with relapsed or refractory small-cell lung cancer (DAREON-5). NCT05882058."},{"key":"10.1016\/j.resinv.2026.101434_bib38b","unstructured":"ClinicalTrials.gov. A study of BI 764532 (Obrixtamig) in combination with other anticancer therapies in DLL3-expressing malignancies (DAREON-8). NCT06077500."}],"container-title":["Respiratory Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212534526000687?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212534526000687?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T13:00:00Z","timestamp":1778850000000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212534526000687"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":60,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S2212534526000687"],"URL":"https:\/\/doi.org\/10.1016\/j.resinv.2026.101434","relation":{},"ISSN":["2212-5345"],"issn-type":[{"value":"2212-5345","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Emerging therapies and translational advances in small cell lung cancer: Overcoming resistance","name":"articletitle","label":"Article Title"},{"value":"Respiratory Investigation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.resinv.2026.101434","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Japanese Respiratory Society. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"101434"}}